Artiva Biotherapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.64 | $-0.63 | +1.6% | Beat |
| Q12026 FY2026 | $-0.88 | $-0.95 | -8.0% | Miss |
| Q42025 FY2025 | $-0.87 | $-0.84 | +3.5% | Beat |
Back to ARTV overview · ARTV holders · ARTV KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.